Unique pharmacological profile of aripiprazole as the phasic component buster
- 5 January 2007
- journal article
- letter
- Published by Springer Nature in Psychopharmacology
- Vol. 191 (3) , 741-743
Abstract
Rationale Aripiprazole is a recently introduced antipsychotic with a unique pharmacological profile, a dopamine partial agonist. Dopaminergic neural transmission has two different components, tonic and phasic, which have different physiological functions, but the effects of aripiprazole on tonic and phasic components are not reported. Objective Studies on antipsychotics including aripiprazole and tonic/phasic dopamine transmission are summarized. Results Antipsychotics exert efficacy without extrapyramidal side effects (EPS’s) when their occupation of dopamine D2 receptors reaches 65–80%. When a “tightly binding” antipsychotic binds 70% of D2 receptors, the remaining 30% are available for endogenous dopamine to bind. These tight antipsychotics suppress dopamine transmission in both tonic/phasic components equally so that similar proportions are kept. Aripiprazole is effective when >90% of D2 receptors are occupied. In this condition, less than 10% of D2 receptors are available for endogenous dopamine to bind; however, EPS’s do not occur because aripiprazole exerts partial dopaminergic agonistic activity. Because the concentration of aripiprazole in the brain is relatively constant and it binds to D2 receptors tightly, the added dopaminergic agonism may show a tonic nature. Thus, aripiprazole suppresses the phasic component relatively more than the tonic component. In contrast, under treatment with “loosely binding” antipsychotics, phasic dopaminergic transmission is relatively preserved. Conclusions Tight antipsychotics suppress both tonic and phasic components equally. Aripiprazole suppresses the phasic component relatively more than the tonic; that is, aripiprazole is a tonic component buster. By contrast, suppression of the phasic component by loosely binding antipsychotics may be relatively weak.Keywords
This publication has 16 references indexed in Scilit:
- The laterodorsal tegmentum is essential for burst firing of ventral tegmental area dopamine neuronsProceedings of the National Academy of Sciences, 2006
- Phasic Dopamine Signaling During Behavior, Reward, and Disease StatesCNS & Neurological Disorders - Drug Targets, 2006
- Pharmacokinetics, Tolerability, and Safety of Aripiprazole following Multiple Oral Dosing in Normal Healthy VolunteersThe Journal of Clinical Pharmacology, 2004
- Afferent modulation of dopamine neuron firing differentially regulates tonic and phasic dopamine transmissionNature Neuroscience, 2003
- Getting Formal with Dopamine and RewardNeuron, 2002
- Transient changes in mesolimbic dopamine and their association with ‘reward’Journal of Neurochemistry, 2002
- Dopamine D2 and D3 Receptor Occupancy in Normal Humans Treated with the Antipsychotic Drug Aripiprazole (OPC 14597) A Study Using Positron Emission Tomography and [11C]RacloprideNeuropsychopharmacology, 2002
- Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action.2000
- Positron Emission Tomographic Analysis of Central D1 and D2 Dopamine Receptor Occupancy in Patients Treated With Classical Neuroleptics and ClozapineArchives of General Psychiatry, 1992
- Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: A hypothesis for the etiology of schizophreniaNeuroscience, 1991